Paper11278747
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.
Liu CH and 8 others. J Biol Chem, 2001. Cited by 688 papers, by iCite.
Cite this record
ConductScience Library. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. Papers, record 11278747. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11278747
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Isoenzymes | Major topic |
| Mammary Neoplasms, Experimental | Major topic |
| Prostaglandin-Endoperoxide Synthases | Major topic |
| Animals | |
| Cyclooxygenase 2 | |
| Female | |
| Gene Expression Regulation, Enzymologic | |
| Mice | |
| Mice, Transgenic |
Source PubMed
Cited by231
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 688 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41512995 | S-nitrosylated COX-2 is a microenvironment-regulated breast cancer cell biomarker of mesenchymal phenotypes. | Exp Cell Res | 2026 | https://conductscience.org/library/papers/41512995 | PubMed |
| 40691279 | Association between low-dose aspirin use and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up. | Br J Cancer | 2025 | https://conductscience.org/library/papers/40691279 | PubMed |
| 40542767 | Anti- Cancer Potential of Diosgenin, a Steroidal Saponin, against Human Oral Cancer Cells. | Asian Pac J Cancer Prev | 2025 | https://conductscience.org/library/papers/40542767 | PubMed |
| 40248271 | Expression of cyclooxygenase-2 (COX-2) in epithelial ovarian cancers in an Indigenous African population of Kano, Nigeria. | Ecancermedicalscience | 2025 | https://conductscience.org/library/papers/40248271 | PubMed |
| 39953784 | Benzo[a]phenoselenazine-based NIR photodynamic therapy for the treatment of COX-2 overexpressing cancer cells. | Future Med Chem | 2025 | https://conductscience.org/library/papers/39953784 | PubMed |
| 39830670 | Dual COX-2/TNF-α Inhibitors as Promising Anti-inflammatory and Cancer Chemopreventive Agents: A Review. | Iran J Pharm Res | 2024 | https://conductscience.org/library/papers/39830670 | PubMed |
| 39717807 | Repurposing of Indomethacin and Naproxen as anticancer agents: progress from 2017 to present. | RSC Adv | 2024 | https://conductscience.org/library/papers/39717807 | PubMed |
| 39652176 | Treatment of cancer-associated fibroblast-like cells with celecoxib enhances the anti-cancer T helper 1/Treg responses in breast cancer. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/39652176 | PubMed |
| 38990306 | Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/38990306 | PubMed |
| 38584541 | Recent Advancements in Refashioning of NSAIDs and their Derivatives as Anticancer Candidates. | Curr Pharm Des | 2024 | https://conductscience.org/library/papers/38584541 | PubMed |
| 38165473 | COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers. | Med Oncol | 2024 | https://conductscience.org/library/papers/38165473 | PubMed |
| 37138287 | Construction of a lipid metabolism-related and immune-associated prognostic score for gastric cancer. | BMC Med Genomics | 2023 | https://conductscience.org/library/papers/37138287 | PubMed |
| 36361772 | Valdecoxib Protects against Cell Apoptosis Induced by Endoplasmic Reticulum Stress via the Inhibition of PERK-ATF4-CHOP Pathway in Experimental Glaucoma. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36361772 | PubMed |
| 35450217 | The Association Between Cyclooxygenase-2 -1195G/A (rs689466) Gene Polymorphism and the Clinicopathology of Lung Cancer in the Japanese Population: A Case-Controlled Study. | Front Genet | 2022 | https://conductscience.org/library/papers/35450217 | PubMed |
| 35008687 | Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/35008687 | PubMed |
| 34640461 | A Systematic Review of the Cyclooxygenase-2 (COX-2) Expression in Rectal Cancer Patients Treated with Preoperative Radiotherapy or Radiochemotherapy. | J Clin Med | 2021 | https://conductscience.org/library/papers/34640461 | PubMed |
| 34529222 | Modulation of endothelium function by fatty acids. | Mol Cell Biochem | 2022 | https://conductscience.org/library/papers/34529222 | PubMed |
| 34351578 | Interactions between exposure to polycyclic aromatic hydrocarbons and xenobiotic metabolism genes, and risk of breast cancer. | Breast Cancer | 2022 | https://conductscience.org/library/papers/34351578 | PubMed |
| 34178680 | The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition. | Front Oncol | 2021 | https://conductscience.org/library/papers/34178680 | PubMed |
| 33972599 | Cyclooxygenase-2 induces neoplastic transformation by inhibiting p53-dependent oncogene-induced senescence. | Sci Rep | 2021 | https://conductscience.org/library/papers/33972599 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MT-CO2 | 4513 | PubTator's text mining | https://conductscience.org/library/genes/4513 | NCBI Gene |
| PTGS2 | 5743 | PubTator's text mining | https://conductscience.org/library/genes/5743 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11278747
GET https://conductscience.org/api/papers/v1/11278747/cited_by?page=2